Q2 2026 Intellia Therapeutics Inc Earnings Call Transcript
Key Points
- Intellia Therapeutics Inc (NTLA) reported positive top-line results from the Phase III HALO trial for LONVOSI in hereditary angioedema (HAE), achieving statistical significance on the primary and all key secondary endpoints, including an 87% reduction in mean monthly attacks versus placebo.
- The company is advancing its rolling BLA submission for LONVOSI with the FDA and expects to announce acceptance by the end of 2026, positioning it for a potential U.S. launch in the first half of 2027 as the world's first in vivo gene editing product.
- Intellia Therapeutics Inc (NTLA) resumed enrollment and dosing in both Phase III trials for NEXI in ATTR after resolving clinical holds, with screening rates rapidly increasing globally and over 650 patients enrolled in the Magnitude trial.
- The company identified a specific HLA allele (C0501) associated with higher-grade transaminase elevations in NEXI trials, enabling the implementation of HLA typing and mitigation strategies to enhance patient safety and informed decision-making.
- Intellia Therapeutics Inc (NTLA) maintains a strong financial position with $628.4 million in cash, sufficient to fund operations into 2028, excluding any potential product revenues from a LONVOSI launch.
- Intellia Therapeutics Inc (NTLA) faces uncertainty in the ATTR market following the disappointing top-line results from the CardioTransform trial of a competing TTR silencer, which has sparked debate about the efficacy of combination therapies.
- The company identified a statistically significant finding that patients carrying the C0501 HLA allele have a higher rate of grade 3 or greater transaminase elevations, potentially limiting the addressable patient population for NEXI.
- Intellia Therapeutics Inc (NTLA) reported a decrease in collaboration revenue to $7.7 million in Q2 2026 from $14.2 million in the prior year quarter, primarily due to reduced revenue from Regeneron.
- The company's net loss widened to $106.6 million in Q2 2026 from $101.3 million in the prior year quarter, reflecting increased G&A expenses tied to commercial infrastructure build-out and higher legal costs.
- Intellia Therapeutics Inc (NTLA) is still awaiting detailed data from the CardioTransform trial and has not yet guided on data timing for its Magnitude trial, leaving uncertainty around the potential need for trial design changes.
Hello and welcome to Intellia Therapeutics second quarter conference call. My name is Chloe and I will be your conference operator today. Please be advised that today's call is being recorded. I would now like to turn the call over to Jason Ferdette, Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.
Thank you, operator, and hello, everyone. Earlier this morning, we issued a press release outlining recent business updates in our second quarter financial results. This document can be found on the Investors and Media section of Intellia's website at intelliatx.com.
At this time, I would like to take a minute to remind listeners that during this call, Intellia management may make certain forward-looking statements. We ask that you refer to our SEC filings available at sec.gov for a discussion of potential risks and uncertainties.
All information presented on this call is current as of today and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
